Qualitative Consumer Research on Acceptance of Long-Acting Pre-Exposure Prophylaxis Products Among Men Having Sex with Men and Medical Practitioners in the United States
| Autor: | Bobby J. Calder, Patrick F. Kiser, Thomas J. Hope, Alex Carballo-Diéguez, Richard T. D'Aquila, Rebecca Giguere, Robert J. Schieffer, Ewa Bryndza Tfaily, George J. Greene |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Health Personnel Immunology Human immunodeficiency virus (HIV) Consumer research HIV Infections medicine.disease_cause 03 medical and health sciences Pre-exposure prophylaxis Sexual and Gender Minorities 0302 clinical medicine Virology Medicine Humans 030212 general & internal medicine Men having sex with men Homosexuality Male Qualitative Research Marketing of Health Services 030505 public health business.industry Focus Groups Middle Aged Patient Acceptance of Health Care PrEP United States Infectious Diseases Long acting Pill Family medicine Delayed-Action Preparations Female Pre-Exposure Prophylaxis 0305 other medical science business |
| Popis: | Pre-exposure prophylaxis (PrEP) with oral Truvada(®) prevents HIV infection. However, the adherence to pill taking required for efficacy has sparked interest in developing new antiretroviral delivery systems that decrease such demands. Long-acting formulations, such as injections and implants, represent promising options that require less frequent adherence. It is important, however, that development of these new modalities be driven by understanding of the value seen in them by target users to maximize their uptake. To identify the key product features that impact user acceptance, we used a three-phase marketing research approach. In this study, we describe the results of the first-phase, qualitative focus group research performed in Chicago and San Francisco that explored subjective perceptions of oral versus alternative PrEP modalities among men having sex with men (MSM) and medical practitioners caring for MSM. Data revealed that potential value in long-acting PrEP lies more in simplifying the lives of users rather than in making them more confident in their adherence. The results provide an important guidance for designing and promoting these future long-acting products to enhance their contribution to increasing the current limited uptake of PrEP that will better stem the HIV epidemic. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|